Table 1 Baseline characteristics of trials included in meta-analysis. CANA canagliflozin, DAPA dapagliflozin, EMPA empagliflozin, PBO placebo, left ventricular ejection LVEF, age and LVEF were reported in Mean, * for median(Q1,Q3), NR, not reported

T2D,n (%)

166(63.1)

1466(58.9)

1856(49.8)

0(0)

2806(44.8)

25(13.1)

125(27.9)

634(52.3)

84(80)

LVEF, %

26.4(8.1)

54.3(8.8)

27.4(6.1)

36.3(8.1)

54.2(8.8)

29.5(8.0)

NR

43.7(16.2)

32.5(9.8)

Male, n (%)

193(73.4)

3312(55.3)

2837(76.1)

54(64.3)

3516(56.1)

162(85.3)

251(55.2)

11(63.1)

77(73.3)

Age,years

61.3(11.5)

71.9(9.4)

66.8(11.0)

62(12.1)

71.7(9.6)

64(8.5)

63.4(13.3)

66.2(12.9)

68.7(11.1)

Interventions

DAPA 10 mg, PBO

EMPA 10 mg, PBO

EMPA 10 mg, PBO

EMPA 10 mg, PBO

DAPA 10 mg, PBO

EMPA 10 mg, PBO

CANA 100 mg, PBO

EMPA 10 mg, PBO

EMPA 10 mg, PBO

Participants,n

263

4988

3730

84

6263

190

448

65

105

Follow-up,weeks

52

52

148

26

169

12

12

12

36

Condition

HFrEF

HFpEF

HFrEF

HFrEF

HFpEF

HFrEF

HF

HF

HFrEF

Country

United States

United States

United States

United States

United States

Denmark

United States

United States

United Kingdom

Completion Date

2019/6/28

2021/4/26

2020/5/28

2020/2/13

2022/3/27

2020/1/17

2021/11/09

2020/03/10

2020/03/18

NCT ID

NCT02653482

NCT03057951

NCT03057977

NCT03485222

NCT03619213

NCT03198585

NCT04252287

NCT03030222

NCT03485092

Study

DEFINE-HF [19, 20]

EMPEROR-Preserved [21,22,23]

EMPEROR-Reduced [8, 24, 25]

EMPA-TROPIS

M [26, 27]

DELIVER [28, 29]

Empire HF [30, 31]

CHIEF-HF [32, 33]

EMBRACE-HF [34]

SUGAR-DM-HF [35]

T2D,n (%)

1983(41.8)

181(55.9)

NR

NR

NR

NR

73(49.7)

50(100)

29(25.9)

LVEF, %

31.1(6.8)

60(54, 65)*

NR

NR

NR

NR

28.3(7.2)

47.3(9.1)

45.5(3.3)

Male, n (%)

3635(76.6)

140(43.2)

232(74.4)

179(56.8)

233(74.4)

320(63.5)

112(76.2)

28(56)

84(75)

Age,years

66.3(10.9)

70(63, 77)*

69.0(10.2)

73.5(8.8)

67.8(10.4)

71.8(9.4)

61.9(11.6)

66.1(7.1)

69(57,78)*

Interventions

DAPA 10 mg, PBO

DAPA 10 mg, PBO

EMPA 10 mg, PBO

EMPA 10 mg, PBO

DAPA 10 mg, PBO

DAPA 10 mg, PBO

DAPA 10 mg, PBO

DAPA 10 mg,CA

NA 100 mg, PBO

EMPA 10 mg, PBO

Participants,n

4744

324

312

313

313

504

147

50

112

Follow-up,weeks

104

12

12

12

16

16

52

26

83

Condition

HFrEF

HFpEF

HFrEF

HFpEF

HFrEF

HFpEF

HFrEF

HFrEF

HFrEF

Country

United States

United States

United States

United States

United States

United States

China

China

China

Completion Date

2019/7/17

2021/8/13

2019/10/07

2019/10/09

2020/03/07

2020/07/09

2020/10/31

2020/12/31

2021/04/30

NCT ID

NCT03036124

NCT03030235

NCT03448419

NCT03448406

NCT03877237

NCT03877224

NR

NR

NR

Study

DAPA-HF [7, 36, 37]

DAPA-Preserved [38, 39]

EMPERIAL-Reduced [40, 41]

EMPERIAL-Preserved [40, 41]

DETERMINE-reduced [42]

DETERMINE-Preserved [43]

Zheng et al [44]

Li et al [45]

Wu et al [46]